Copyright
©2014 Baishideng Publishing Group Inc.
World J Clin Oncol. Aug 10, 2014; 5(3): 374-381
Published online Aug 10, 2014. doi: 10.5306/wjco.v5.i3.374
Published online Aug 10, 2014. doi: 10.5306/wjco.v5.i3.374
Table 1 The impact of CYP2D*6 genotype in clinical parameters
Ref. | Parameter | Extensive metabolisers | Intermediate metabolisers | Poor metamolisers |
Goetz et al[8] | RFS DFS OS | NS (P = 0.075) NS (P = 0.097) NS | Worse (P = 0.005) Worse (P = 0.008) NS | |
Scroth et al[9,10] | RR MR | 14.90% 16.70% | 20.90% 18.00% | 29.00% 22.80% |
Ramóny Cajal et al[12] | DFS | 118 mo | 114 mo | 98 mo |
Bijl et al[13] | RBCM | NS | Increased (P = 0.041) | |
Newman et al[16] | OS | Worse | ||
Karle et al[17] | PFS | 14 mo | 9 mo | |
Abraham et al[20] | BCSS | NS | ||
Nowell[23] | BCR, OS | NS | NS | |
Rae et al[25] | RR | NS | NS | |
Regan et al[26] | BCE | NS | NS |
- Citation: Markopoulos C, Kykalos S, Mantas D. Impact of CYP2D*6 in the adjuvant treatment of breast cancer patients with tamoxifen. World J Clin Oncol 2014; 5(3): 374-381
- URL: https://www.wjgnet.com/2218-4333/full/v5/i3/374.htm
- DOI: https://dx.doi.org/10.5306/wjco.v5.i3.374